New hope for rare lung cancer: targeted pill NVL-330 enters human trials

NCT ID NCT06521554

Recruiting now Disease control Sponsor: Nuvalent Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new oral drug, NVL-330, in about 200 adults with advanced or metastatic non-small cell lung cancer that has specific HER2 mutations. The goal is to find the safest and most effective dose and see if the drug can shrink tumors. Participants must have HER2-altered lung cancer and measurable disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC HER2-ALTERED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Chris O'Brien Lifehouse
RECRUITING

Camperdown, New South Wales, NSW 2050, Australia
City of Hope - Lennar
RECRUITING

Irvine, California, 92618, United States
Cross Cancer Institute
RECRUITING

Edmonton, Alberta, T6G 1Z2, Canada
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Georgetown University Medical Center
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Henry Ford Cancer Center
RECRUITING

Detroit, Michigan, 48242, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Medical Center
RECRUITING

Baltimore, Maryland, 21224, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
North Shore Health Hub
RECRUITING

Saint Leonards, New South Wales, 2065, Australia
OSU Brain and Spine Hospital
RECRUITING

Columbus, Ohio, 43210, United States
Princess Margaret Cancer Center - University Health Network
RECRUITING

Toronto, Ontario, M5G 1L7, Canada
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
Sibley Memorial Hospital
RECRUITING

Washington D.C., District of Columbia, 20016, United States
Stanford Cancer Institute
RECRUITING

Stanford, California, 94305, United States
Sylvester Comprehensive Cancer Center
RECRUITING

Miami, Florida, 33136, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of California, Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.